An orally bioavailable small molecule antagonist of VISTA and VSIG8 signaling pathways shows potent anti-tumor activity

被引：0
|
作者：
Sasikumar, Pottayil [1 ]
Naremaddepalli, Sudarshan [1 ]
Ramachandra, Raghuveer [1 ]
Gowda, Nagesh [1 ]
Alluri, Govardhan [1 ]
Yerramsetti, Manikyalarao [1 ]
Adurthi, Sreenivas [1 ]
Mani, Jiju [1 ]
Nair, Rashmi [1 ]
Dhudashiya, Amit [1 ]
Dodheri, Samiulla [1 ]
Gowda, Nagaraj [1 ]
Ramachandra, Murali [1 ]
机构：
[1] Aurigene Discovery Technol Ltd, Bangalore, Karnataka, India
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P354
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Anti-tumor activity of beauvericin: focus on intracellular signaling pathways
    Liu, Ruoxuan
    Ouyang, Jie
    Li, Liming
    MYCOTOXIN RESEARCH, 2024, 40 (04) : 535 - 546
  • [12] Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Inhibitors of CDK8 for the Treatment of Cancer
    Li, Yangguang
    Liu, Yingtao
    Wu, Jianping
    Liu, Xiaosong
    Wang, Lin
    Wang, Ju
    Yu, Jiaojiao
    Qi, Hongyun
    Qin, Luoheng
    Ding, Xiao
    Ren, Feng
    Zhavoronkov, Alex
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (08) : 5439 - 5452
  • [13] BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models
    Lundgren, Karen
    Zhang, Hong
    Kamal, Adeela
    Lough, Rachel
    Timple, Noelito
    Sensintaffar, John
    Busch, David
    Yang, Cindy
    Neely, Laura
    Khan, Samina
    Hong, Kevin
    Kasibhatla, Srinivas
    Boehm, Marcus
    Burrows, Francis
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3485S - 3485S
  • [14] Discovery of potent, selective, and orally bioavailable GSPT1 degraders and their preclinical anti-tumor activity in acute myeloid leukemia and solid tumors
    Joo, Min Sung
    Lee, JaeYung
    Kim, Eun-Jung
    Ki, Dong Hyuk
    Choi, Hunmi
    Nam, Joonwoo
    Park, Jaewoo
    Kang, Keon Wook
    Han, Wooseok
    CANCER RESEARCH, 2023, 83 (07)
  • [15] LGD-6972, a Potent, Orally-Bioavailable, Small Molecule Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes
    Vajda, Eric G.
    Potter, Scott C.
    Fujitaki, James M.
    Reddy, Raja K.
    Van Poelje, Paul D.
    Lee, Yong-Hee
    Henderson, Ian
    Zhi, Lin
    Marschke, Keith B.
    DIABETES, 2012, 61 : A252 - A252
  • [16] BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity
    Scholz, Arne
    Luecking, Ulrich
    Siemeister, Gerhard
    Lienau, Philip
    Eis, Knut
    Wengner, Antje
    Petersen, Kirstin
    Boemer, Ulf
    Nussbaumer, Peter
    Choidas, Axel
    Ruehter, Gerd
    Eickhoff, Jan
    Schultz-Fademrecht, Carsten
    Klebl, Bert
    Ince, Stuart
    von Nussbaum, Franz
    Mumberg, Dominik
    Brands, Michael
    Ziegelbauer, Karl
    CANCER RESEARCH, 2014, 74 (19)
  • [17] CX-5461, a novel, orally bioavailable selective small molecule inhibitor of RNA polymerase I transcription, induces autophagy and shows potent antitumor activity
    Drygin, D.
    Lin, A.
    Haddach, M.
    Ho, C.
    Bliesath, J.
    Proffitt, C.
    Schwaebe, M. T. K.
    Rice, W. A. K.
    Anderes, K. L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 108 - 108
  • [18] An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer
    Feldmann, Georg
    Fendrich, Volker
    McGovern, Karen
    Bedja, Djahida
    Bisht, Savita
    Alvarez, Hector
    Koorstra, Jan-Bart M.
    Habbe, Nils
    Karikari, Collins
    Mullendore, Michael
    Gabrielson, Kathleen L.
    Sharma, Rajni
    Matsui, William
    Maitra, Anirban
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (09) : 2725 - 2735
  • [19] TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo
    Liang, Apeng
    Dong, Shengli
    Liu, Guangbin
    Guo, Zhengfei
    Li, Meihua
    Han, Shuaibo
    Cao, Yundi
    Tu, Yian
    Zhou, Chao
    Yu, Yu
    Xiao, Linglin
    Huang, Wei
    Yang, Xinlong
    Fang, Lian
    Li, Haoyun
    Niu, Chengshan
    Jiang, Mingyu
    Xing, Feng
    Chen, Shaoqing
    Li, Jun
    Wu, Yusheng
    CANCER RESEARCH, 2023, 83 (07)
  • [20] Potent anti-tumor activity correlated with inhibition of DNA damage response genes with highly selective and orally bioavailable CDK12 covalent inhibitors
    Poddutoori, R.
    Rajagopalan, S.
    Mukherjee, S.
    Marappan, S.
    Samiulla, D.
    Nayak, S.
    Sivakumar, S.
    Ravindra, M.
    Gore, S.
    Dhudashiya, A.
    Charamanna, K.
    Daginakatte, G.
    Chelur, S.
    Ramachandra, M.
    Samajdar, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E94 - E95
12345